Jag Grewal, BSc Hons, MSC, MBA
Chief Executive appointed to the Company on 30 June 2011
Jag joined Omega in June 2011 as Group Sales and Marketing Director. He has worked in the medical diagnostics industry for over 25 years having started out as a Clinical Biochemist in the NHS. In 1995 he joined Beckman Instruments where he developed a career spanning 15 years in sales and marketing holding a variety of positions in sales, product management and marketing management. In 2009 he left his position of Northern Europe Marketing Manager to join Serco Health, where he helped create the first joint venture within UK pathology between Serco and Guy’s and St Thomas’ Hospital. He is also past Chairman and current Treasurer of the British In Vitro Diagnostics Association (BIVDA).
Jag was appointed as CEO in January 2022, replacing Colin King. Prior to this appointment, Jag was responsible for managing the Health and Nutrition division.
Dr Simon Douglas, PhD, MPhil, BSc (hons)
Non-Executive Chairman appointed to the Company on 11 February 2021
Chairman of the Remuneration Committee and member of the Audit Committee
Simon was appointed Chairman in February 2021. He has over 30 years’ experience in the biotech industry, including 10 years working for Amersham International (now GE), ICI and Zeneca (now Astra Zeneca), in a variety of commercial and technical positions, and over five years with Tepnel Life Sciences plc (now Hologic Inc), a London Stock Exchange listed diagnostic company where he was Chief Executive. He has been the CEO/Executive Chairman on three other venture capital backed Life Science companies and headed up the trade sale of two of these. He is currently Chairman of Fusion Antibodies plc, an AIM listed CRO providing services for the discovery and development of antibody-based therapies, C-Major Medical, a venture capital backed Medical Device Company and Chairman of Cambridge start up, HexagonFab.
Chris Lea, BSc Hons, ACA
Chief Financial Officer and Company Secretary appointed to the Company on 30 August 2021
Chris joined Omega on 30 August 2021 as Chief Financial Officer and Company Secretary. He is responsible for finance, tax, auditing, company secretarial and supporting the CEO with investor relations. He was previously CFO of two other AIM-listed companies, IndigoVision Group plc and Superglass Holdings PLC, both of which were successfully turned around under Chris’ management and were subsequently acquired by larger corporations. IndigoVision was one of the larger independent, end-to-end CCTV system manufacturers, operating worldwide from its Edinburgh HQ and was acquired by Motorola Solutions, Inc in June 2020. Prior to its sale in 2016, Superglass was the UK’s only independent manufacturer of glass wool insulation and is now part of TechnoNICOL International, a leading producer of construction materials.
Prior to his public company roles, Chris was CFO of Aviagen Europe, the world’s largest poultry breeding company, where he helped grow Aviagen’s European business five-fold over a 10-year period, through a combination of organic growth and multiple strategic acquisitions. Chris spent 15 years with KPMG, holding various roles in their audit and corporate finance business. He holds a BSc (Hons) in Physics from Nottingham University and is a member of the Institute of Chartered Accountants in England and Wales.
Jeremy Millard, BA (hons) M.Eng, FCA
Non-Executive Director appointed to the Company on 1 March 201
Chairman of the Audit Committee and member of the Remuneration Committee.
Jeremy has 20 years’ investment banking experience and was previously a partner at Smith Square Partners LLP where he provided strategic and corporate finance advice to clients in the science, technology and telecommunications sectors, prior to which he headed up the technology practice at Rothschild in London. Jeremy runs FCA-regulated corporate finance business Iridium Corporate Finance and is also currently a Non-executive Director and Chairman of the Audit Committee of AIM-listed Ilika Plc as well as sitting on the Boards of a number of other private UK companies.